当前位置: 首页 > 详情页

Clinical Controlled Study of Integrative Chinese and Western Medicine in Treating 49 Cases of SARS

| 认领 | 导出 |

文献详情

资源类型:
机构: [1]WangjingHospitalChinaAcademyofTraditionalChineseMedicineBeijing100102 [2]BeijingTiantanHospital
出处:
ISSN:

关键词: severe acute respiratory syndrome integrative Chinese and western medicine treatment corticosteroid clinical study

摘要:
Objective: To evaluate the efficacy of integrative Chinese and western medicine (ICWM)in treating severe acute respiratory syndrome (SARS) patients. Methods: Through parallel control design,49 SARS patients were observed. Used as control, there were in the western medicine (WM) group 29 patients, who were treated with Ribavirin, Levofloxacin, Thymopentin, Azithromycin, methylprednisolone,etc. , on the basis of "Recommended Protocol for Infectious Atypical Pneumonia" (abbreviated as "Recommended Protocol") issueed by Ministry of Health. As the treated group, there were in the ICWM 20 cascs. The protocol for treatment of SARS in "Special Science and Technological Action to Prevent and Treat SARS" (abbreviated as "Special S-T Action"), issued by Ministry of Science and Technology, together with the same WM as those for the control group. Results: (1) Time from the disease onset to the symptom improvement were 5.10±2.83 days and 7.62±2.27 days in ICWM and WM group respectively,P<0. 05; (2) As to corticosteroid (CS) amount and days before reducing dosage, 2 groups showed no significant difference, P>0.05; (3) There was no significant difference in the time from disease onset to the body temperature normalization and the total amount of CS and the duration of using CS before reducing it to 80 mg between the ICWM group and the WM group; (4) The days and amounts for use CS after reducing between the ICWM group and the WM group were significantly different (P<0. 05). Conclusion:There were obvious advantages in ICWM to treat SARS, compared with that of WM alone, especially in improving the clinical symptoms, promoting the recovery of immune function, promoting the absorption of pulmonary inflammation and reducing the dosage and duration of CS treatment.

语种:
中科院(CAS)分区:
出版当年[2002]版:
最新[2023]版:
大类 | 3 区 医学
小类 | 4 区 全科医学与补充医学
第一作者:
第一作者机构: [1]WangjingHospitalChinaAcademyofTraditionalChineseMedicineBeijing100102
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:16409 今日访问量:0 总访问量:869 更新日期:2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 首都医科大学宣武医院 技术支持:重庆聚合科技有限公司 地址:北京市西城区长椿街45号宣武医院